Replies to post #164642 on Cytodyn Inc (CYDY)

[misiu143]

Yes , true ...Lenzilumab is run differently then other drugs ,
oh no ,
sorry , Remdesivir is run the same way.

They started a special study .. Adaptive Design Study , approved by FDA mostly to Dr Fauci favorites ...

Where management " PICK" during the active studies as CEO said , without penalties

See what they may choose from the active results as a primary endpoint , and then declare a victory..LOL.

We never heard about one patient coming off ECMO after lenzilumab , as with leronlimab...
Oh yeh , someone posted before , they just don't like to talk about it ..LOL..

And lenzilumab has no drug even to use if they need too , per CEO recently ..

" we AIM to have 100,000 doses in 12 months "
this equal to about 33,000 patients , since each need 3 doses..

I send this question to HGEN , I also called and left the message to Allen , I guess he is an IR , I never received any answer ..well , for me this is an answer..

Why did they need a special design by NIH and FDA , if they don't even have enough of drug..

But they most probably will have fast EUA !!

With our leronlimab , we expecting , few mills vials a month with any approval..

How great is that !!!


All IMO.